Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer
Latest Information Update: 24 May 2025
At a glance
- Drugs Bevacizumab (Primary) ; CDX 1140 (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 30 Jan 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 30 Dec 2023 to 1 Mar 2024.
- 30 Jan 2024 Status changed from not yet recruiting to recruiting.
- 29 Nov 2023 Planned End Date changed from 30 Oct 2026 to 30 Dec 2026.